<DOC>
	<DOCNO>NCT02046031</DOCNO>
	<brief_summary>To explore rule absorption , distribution , metabolism elimination intravenous administration Ginkgolides Meglumine Injection healthy subject . The plasma drug profile important assess potential clinical drug-drug interaction .</brief_summary>
	<brief_title>Preliminary Study Pharmacokinetics Ginkgolides Meglumine Injection .</brief_title>
	<detailed_description>Ginkgolides Meglumine Injection jointly develop China Pharmaceutical University Jiangsu Kanion Pharmaceutical Co. , Ltd. Its pharmacal ingredient ginkgo lactones A , ginkgo lactone B , ginkgo lactone K , etc ; Excipients meglumine , citric acid , sodium chloride . It use treat stroke ( mild-to-moderate cerebral infarction ) recovery phlegm Syndrome Intermingled Phlegm Blood Stasis . The aim study explore rule absorption , distribution , metabolism elimination intravenous administration Ginkgolides Meglumine Injection healthy subject . The plasma drug profile important assess potential clinical drug-drug interaction . Biological sample include blood urine PK collect study . In first stage , biological sample two subject collect different time point . In second stage , biological sample another two subject collect time point adjust accord result first stage .</detailed_description>
	<criteria>Ages 1840 , 10 year apart . Both male female . Subjects standard weight ( generally less 50 kg ) , body mass index ( BMI ) within 1925 . Subjects weight ( kg ) differ much . All physical examination ( include ECG , kidney function , liver function , blood routine , urine routine , etc ) normal . History disease : history diseases gastrointestinal tract , reproductive tract , urinary tract , heart , liver , kidney , lung , nervous system , metabolism , history allergy orthostatic hypotension . After tell possible adverse reaction associate drug , subject sign informed consent promise complete examination . Subjects communicate medical staff , subject cerebral insufficiency psychological problem . Female subject partner male subject plan pregnant . Subjects primary disease significant organ . Subjects history drug dependence psychosis last 2 year . Subjects blood loss blood donation 200 mL 3 month prior baseline . Subjects take part clinical trial 3 month prior baseline . Subjects abuse alcohol drug . Pregnancy breastfeed subject . Subjects find clinical significance abnormal check information physical examination . Known allergies serious side effect two kind food drug past . Subjects take drug previous 2 week . Subjects unexplained infection . The subject could complete study opinion Principal Investigator due reason . Positive HIV„ÄÅHCV HBsAg test result . A female subject whose pregnancy test positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Ischemic stroke</keyword>
	<keyword>safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ginkgolides Meglumine Injection</keyword>
</DOC>